{"generic":"Ranibizumab","drugs":["Lucentis","Ranibizumab"],"mono":{"0":{"id":"jwhhs0","title":"Generic Names","mono":"Ranibizumab"},"1":{"id":"jwhhs1","title":"Dosing and Indications","sub":[{"id":"jwhhs1b4","title":"Adult Dosing","mono":"<ul><li>Prior to and 30 minutes after intravitreal injection, evaluate intraocular pressure using tonometry.<\/li><li><b>Choroidal retinal neovascularization, Secondary to pathologic myopia:<\/b> 0.5 mg\/0.05 mL INTRAVITREAL injection and monthly dosing as needed (study dose)<\/li><li><b>Diabetic macular edema:<\/b> 0.3 mg (0.05 mL of 6 mg\/mL ranibizumab solution) INTRAVITREALLY once monthly (approximately 28 days); give adequate anesthesia and a broad-spectrum microbicide prior to injection<\/li><li><b>Diabetic macular edema - Diabetic retinopathy:<\/b> 0.3 mg (0.05 mL of 6 mg\/mL ranibizumab solution) INTRAVITREALLY once monthly (approximately 28 days); give adequate anesthesia and a broad-spectrum microbicide prior to injection<\/li><li><b>Exudative age-related macular degeneration:<\/b> 0.5 mg (0.05 mL of 10 mg\/mL ranibizumab solution) by INTRAVITREAL injection once a month (approximately 28 days); give adequate anesthesia and a broad-spectrum microbicide prior to injection<\/li><li><b>Exudative age-related macular degeneration:<\/b> alternative dosing: may reduce to 0.5 mg by INTRAVITREAL injection every 3 months after the first 4 monthly injections if monthly injections are not feasible; dose will be less effective, leading to an approximate 5-letter (1-line) average loss of visual acuity over the following 9 months OR may reduce to 0.5 mg by INTRAVITREAL injection monthly for 3 months followed by less frequent injections (average 4 to 5 injections over 9 months) if monthly injections are not feasible; dose will be less effective, leading to a maintenance of visual acuity compared with a 1- to 2-letter gain with monthly injections; give adequate anesthesia and a broad-spectrum microbicide prior to injection<\/li><li><b>Macular retinal edema - Thrombosis of retinal vein:<\/b> 0.5 mg (0.05 mL of 10 mg\/mL ranibizumab solution) by INTRAVITREAL injection once a month (approximately 28 days); give adequate anesthesia and a broad-spectrum microbicide prior to injection<\/li><\/ul>"},{"id":"jwhhs1b5","title":"Pediatric Dosing","mono":"Safety and efficacy not established in pediatric patients "},{"id":"jwhhs1b6","title":"Dose Adjustments","mono":"<b>Geriatric:<\/b> No adjustments needed."},{"id":"jwhhs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Diabetic macular edema<\/li><li>Diabetic macular edema - Diabetic retinopathy<\/li><li>Exudative age-related macular degeneration<\/li><li>Macular retinal edema - Thrombosis of retinal vein<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Choroidal retinal neovascularization, Secondary to pathologic myopia<br\/>"}]},"3":{"id":"jwhhs3","title":"Contraindications\/Warnings","sub":[{"id":"jwhhs3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to ranibizumab or any component of the product; reactions may manifest as severe intraocular inflammation<\/li><li>infection, ocular or periocular<\/li><\/ul>"},{"id":"jwhhs3b10","title":"Precautions","mono":"<ul><li>arterial thromboembolic events (nonfatal stroke, nonfatal myocardial infarction, or vascular death) have occurred<\/li><li>endophthalmitis has been reported; monitoring recommended<\/li><li>intraocular pressure increase has been observed within 60 minutes of injection; monitoring recommended<\/li><li>retinal detachment has occurred<\/li><li>report suspected adverse events to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jwhhs3b11","title":"Pregnancy Category","mono":"D (AUS)<br\/>"},{"id":"jwhhs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jwhhs5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Cataract (2% to 17%), Conjunctival hemorrhage (47% to 74%), Eye irritation (7% to 15%), Foreign body sensation, in the eyes (7% to 16%), Inflammatory disorder of the eye (4% to 18%), Pain in eye (17% to 35%), Raised intraocular pressure (7% to 24%), Visual disturbance (5% to 18%), Vitreous detachment (4% to 21%), Vitreous floaters (7% to 27%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Arterial thromboembolism (0.8% to 10.8%), Atrial fibrillation (1% to 5%)<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident (0.2% to 4.8%)<\/li><li><b>Ophthalmic:<\/b>Atrophic iris (2%), Central retinal vein occlusion - ischemic, Endophthalmitis (1.9%), Glaucoma (2%), Iridocyclitis (52.9% to 73.6%), Retinal detachment, Retinal hemorrhage (3.9% to 24.5%), Retinal tear (1.9%), Thrombosis of retinal artery (2%)<\/li><\/ul>"},"6":{"id":"jwhhs6","title":"Drug Name Info","sub":{"0":{"id":"jwhhs6b17","title":"US Trade Names","mono":"Lucentis<br\/>"},"2":{"id":"jwhhs6b19","title":"Class","mono":"<ul><li>Monoclonal Antibody Fragment<\/li><li>Ophthalmologic Agent<\/li><\/ul>"},"3":{"id":"jwhhs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jwhhs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jwhhs7","title":"Mechanism Of Action","mono":"Ranibizumab inhibits the human vascular endothelial growth factor A (VEGF-A) by binding to its active forms, thereby preventing ocular angiogenesis by VEGF-A including reduced endothelial cell proliferation, vascular leakage, and new blood vessel formation.<br\/>"},"8":{"id":"jwhhs8","title":"Pharmacokinetics","sub":{"0":{"id":"jwhhs8b23","title":"Absorption","mono":"Tmax, intravitreal: Approximately 1 day <br\/>"},"4":{"id":"jwhhs8b27","title":"Elimination Half Life","mono":"Vitreous t(1\/2): Approximately 9 days <br\/>"}}},"9":{"id":"jwhhs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For ophthalmic intravitreal injection only<br\/><\/li><li><b>Intravitreal<\/b><br\/><ul><li>Use 1 vial per eye; change sterile field, gloves, drapes, eyelid speculum, filter, and injection needles before administration to the other eye<\/li><li>Withdraw the entire content (0.2 mL) of ranibizumab through a 5-micron, 19-gauge filter needle, switch to a 30-gauge x 0.5-inch needle and purge content to 0.05 mL before administering<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jwhhs10","title":"Monitoring","mono":"<ul><li>maintenance or improvement in visual acuity indicates efficacy<\/li><li>intraocular pressure elevations; tonometry before and 30 minutes after injection<\/li><li>perfusion of optic nerve head; immediately after injection<\/li><li>signs and symptoms of endophthalmitis (redness, sensitivity to light, pain, vision changes); after injection<\/li><li>signs and symptoms of retinal detachment; after injection<\/li><\/ul>"},"11":{"id":"jwhhs11","title":"How Supplied","mono":"<b>Lucentis<\/b><br\/>Intraocular Solution: 0.3 MG\/0.05 ML, 0.5 MG\/0.05 ML<br\/>"},"13":{"id":"jwhhs13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to immediately report signs\/symptoms of endophthalmitis (eye pain or redness, sensitivity to light, or vision changes).<\/li><li>Advise patient to immediately report signs\/symptoms of myocardial infarction or stroke.<\/li><li>Drug may cause conjunctival hemorrhage, increased intraocular pressure, eye pain, vitreous floaters, and intraocular inflammation.<\/li><\/ul>"}}}